DSM informs market on the announced sale of DSM Sinochem Pharmaceuticals to Bain Capital
DSM will receive about €250 million for its equity stake, excluding an earn-out (estimated at around €50m) and transaction costs. DSM anticipates a book profit on the transaction to be recognized upon closing. DSM expects to receive approximately €275 million in cash following closing, including repayment of debt and after transaction costs. More information regarding the acquisition of DSP by Bain Capital can be found in the press release issued by Bain Capital and DSP on 29 June 2018.